Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D3NTA9
|
|||
| Drug Name |
MK-8504
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Human immunodeficiency virus-1 infection [ICD-11: 1C62; ICD-10: B20-B24] | Phase 1 | [1] | |
| Company |
Merck
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Human immunodeficiency virus Reverse transcriptase (HIV RT) | Target Info | Inhibitor | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03188523) Activity of MK-8504 in Anti-retroviral-naive, Human Immunodeficiency Virus 1 (HIV-1) Infected Participants (MK-8504-002). U.S. National Institutes of Health. | |||
| REF 2 | ClinicalTrials.gov (NCT03188523) Activity of MK-8504 in Anti-retroviral-naive, Human Immunodeficiency Virus 1 (HIV-1) Infected Participants (MK-8504-002). U.S. National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.